Contrast-induced nephropathy in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention

Angiology

Volumn 65, Issue 1, 2014, Pages 37-42

  Elbasan, Zafer ^a   Şahin, Durmuş Yildiray ^a   Gür, Mustafa ^a   Kuloǧlu, Osman ^a   Kivrak, Ali ^a   Içen, Yahya Kemal ^a   Türkoǧlu, Caner ^a   Yildirim, Arafat ^a   Özdoǧru, Ibrahim ^b   Çayli, Murat ^a  

^a ADANA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

contrast media; myocardial infarction; nephropathy; SYNTAX score; uric acid

Indexed keywords

IOMEPROL; URIC ACID; CONTRAST MEDIUM;

ADULT; ARTICLE; CONTRAST INDUCED NEPHROPATHY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; SCORING SYSTEM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; URIC ACID BLOOD LEVEL; ADVERSE EFFECTS; AGED; BLOOD; CHEMICALLY INDUCED; CORONARY ANGIOGRAPHY; KIDNEY DISEASE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREVALENCE; RADIOGRAPHY;

ADULT; AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; URIC ACID;

EID: 84888609586     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712463816     Document Type: Article

References (39)

1. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous interventions. J Am Coll Cardiol. 2002 ; 39 (7). 1113-1119
2. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002 ; 105 (19). 2259-2264
3. Gupta R, Gurm HS, Bhatt DL, Chew DP, Ellis SG.. Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv. 2005 ; 64 (4). 442-448
4. Liss P, Persson PB, Hansell P, Lagerqvist B. Renal failure in 57,925 patients undergoing coronary procedures using iso-osmolar or low osmolar contrast media. Kidney Int. 2006 ; 70 (10). 1811-1817
5. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. Eurointervention. 2005 ; 1 (2). 219-227
6. Magro M, Nauta ST, Simsek C, et al. Usefulness of the SYNTAX score to predict «no reflow» in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol. 2012 ; 109 (5). 601-606
7. Capodanno D, Di Salvo ME, Cincotta G, Miano M, Tamburino C, Tamburino C. Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease. Circ Cardiovasc Interv. 2009 ; 2 (4). 302-308
8. Coskun U, Orta Kilickesmez K, Abaci O, et al. The relationship between chronic kidney disease and SYNTAX score. Angiology. 2011 ; 62 (6). 504-508
9. Kilickesmez KO, Abaci O, Okcun B, et al. Chronic kidney disease as a predictor of coronary lesion morphology. Angiology. 2010 ; 61 (4). 344-349
10. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999 ; 131 (1). 7-13
11. Freedman DS, Williamson DF, Gunter EW, Byers T.. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1995 ; 141 (7). 637-644
12. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002 ; 13 (12). 2888-2897
13. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980 ; 93 (6). 817-821
14. Sahin DY, Gur M, Elbasan Z, et al. Mean platelet volume and extent and complexity of coronary artery disease in diabetic and nondiabetic patients with ST elevation myocardial infarction. Angiology. 2012. doi: 10.1177/ 0003319712460423 ;:
15. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000 ; 21 (18). 1502-1513
16. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989 ; 2 (5). 358-367
17. Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol. 2003 ; 76 (908). 513-518
18. Raposeiras-Roubín S, Aguiar-Souto P, Barreiro-Pardal C, et al. GRACE risk score predicts contrast-induced nephropathy in patients with acute coronary syndrome and normal renal function [published online February 1, 2012]. Angiology. :
19. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008 ; 51 (15). 1419-1428
20. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997 ; 103 (5). 368-375
21. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004 ; 44 (7). 1393-1399
22. Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011 ; 21 (12). 2527-2541
23. Paraskevas KI, Giannoukas AD, Kotsikoris I., Mikhailidis DP. Contrast-induced nephropathy and the vascular patient. Angiology. 2010 ; 61 (8). 721-723
24. Özhan H, Erden I, Ordu S, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 2010 ; 61 (7). 711-714
25. Lindsay J, Canos DA, Apple S, Pinnow EE, Aggrey GK, Pichard AD. Causes of acute renal dysfunction after percutaneous coronary intervention and comparison of late mortality rates with postprocedure rise of creatine kinase-MB versus rise of serum creatinine. Am J Cardiol. 2004 ; 94 (6). 786-789
26. Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int. 2005 ; 67 (2). 706-713
27. Iakovou I, Dangas G, Mehran R, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol. 2003 ; 15 (1). 18-22
28. Toprak O, Cirit M, Esi E, Postaci N, Yesil M, Bayata S. Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease. Catheter Cardiovasc Interv. 2006 ; 67 (2). 227-235
29. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takashita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001 ; 24 (6). 691-697
30. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary arteriolopathy in rats by a blood pressure independent mechanism. Am J Physiol Renal Physiol. 2002 ; 282 (6). F991 - F997
31. Mazzali M, Kim YG, Suga S, et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation. 2001 ; 71 (7). 900-905
32. McCullough PA. Multimodality prevention of contrast-induced acute kidney injury. Am J Kidney Dis. 2008 ; 51 (2). 169-172
33. Gao F, Zhou YJ, Zhu X, Wang ZJ, Yang SW, Shen H. C-reactive protein and the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. Am J Nephrol. 2011 ; 34 (3). 203-210
34. Katholi RE, Woods WT, Taylor GJ, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998 ; 32 (1). 64-71
35. Zhang T, Shen LH, Hu LH, He B. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol. 2011 ; 33 (4). 344-351
36. Corry DB, Eslami P, Yamamoto K, Nyby MD, Tuck Makino H,. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008 ; 26 (2). 269-275
37. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005 ; 25 (1). 39-42
38. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: molecular mechanisms and clinical implications. J Cardiol. 2012 ; 59 (3). 235-242
39. Shaker OG, El-Shehaby A, El-Khatib M. Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. Angiology. 2010 ; 61 (8). 731-736